To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: RSNA: New Interventional Approaches Promoted for Budd-Chiari Syndrome URL: http://www.pslgroup.com/dg/20EEA2.htm Doctor's Guide November 29, 2001
By Peggy Peck Special to DG News
CHICAGO, IL -- November 29, 2001 -- New interventional technologies, including angioplasty, transjugular intrahepatic portosystemic stunt or stenting following recanalization, achieved success rates ranging from 92 percent to 100 percent in a consecutive series of 103 patients with Budd-Chiari Syndrome.
Dr. Ke Xu of First Affiliated Hospital, in Shen Yang, People's Republic of China, presented the findings yesterday (Nov. 28) at the 87th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), in Chicago, Illinois.
Seventy-three of the 103 patients in the series were men and the ages ranged from 16 to 63 years, Dr. Xu said. The duration of symptoms ranged from one to 10 years. Fifty-nine patients were opened with inferior vena cava recanalization by "setting up opposite sign venography trace via transjugular and transfemoral approach," Dr. Xu said.
Seventeen patients with hepatic vein occlusion were opened with hepatic vein recanalization via transjugular approach, he said. All Budd-Chiari Syndrome (BCS) patients were treated with angioplasty, transjugular intrahepatic portosystemic stunt (TIPS) or stenting after recanalization.
Inferior vena cava recanalization was successful in 58 of 59 patients and hepatic vein recanalization was successful in 16 of 17 patients. Forty-two patients were treated with angioplasty with a "100 percent success rate," he said. But 24 of these patients restenosed and were subsequently stented. Among 48 patients treated with primary stenting the success rate was 92.3 percent. Five patients underwent TIPS with a 100 percent success rate, he said.
After 51 months of follow-up the patency rate for angioplasty patients was 59 percent, compared to 87 percent patency rate for stent patients after 34 months, he said.
Eight patients died during follow-up ranging from seven to 64 months, one from infection, four from hepatic failure and three due to hemorrage.
Dr. Xu concluded, "new interventional techniques are safe and reliable in treatment of BCS."
Dr. Ziv Haskel, director of interventional radiology research laboratory at Columbia University, in New York, who moderated the RSNA session at which Dr. Xu presented his findings, said the treatments were very different from standard BCS treatment, which relies on TIPS.
Dr. Haskel noted that "many years of follow-up with TIPS demonstrates that we are preventing progression of disease." He said that it will require "much longer follow-up" to demonstrate the same results with the "new high tech treatments." --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.